On cancer chemoprevention: Complications and limitations of some proposed strategies

Carcinogenesis

Volumn 16, Issue 4, 1995, Pages 971-973

  Paolini, M ^a,b   Mesirca, R ^a   Gialluca, N ^c   Bauer, C ^c   Biagi, G L ^a   Cantelli forti, G ^a,d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c Laboratories of Biochemistry ^*  (Italy)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P 450 ENZYME SYSTEM; CYTOCHROME P450; ISOENZYME;

BIOSYNTHESIS; ENZYME INDUCTION; ENZYMOLOGY; HUMAN; NEOPLASM; NOTE;

ANTICARCINOGENIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; HUMAN; ISOENZYMES; NEOPLASMS;

EID: 0029285208     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/16.4.971     Document Type: Letter

References (24)

1. Morse, M.A. and Stoner, G.D. (1993) Cancer chemoprevention: principles and prospects. Carcinogenesis, 14, 1737-1746.
2. Paolini, J.V.L., Bauer, C., Biagi, G.L. and Cantelli-Forti, G. (1989) Do cytochromes P448 and P450 have different functions? Biochem. Pharmacol., 38, 2223-2225.
3. Bast, A. (1986) Is formation of reactive oxygen by cytochrome P450 perilous and predictable? Trends Pharmacol. Sci, 00, 266-270.
4. Paolini, M., Bauer, C., Biagi, G.L. and Cantelli-Forti, G. (1993) Cocktail strategy, complications and limitations. J. Clin. Pharmacol. 33, 1011-1012.
5. Fraga, C.G., Shigenaga, M.K., Park, J.W., Degan, P. and Ames, B.N. (1990) Oxidative damage to DNA during aging: 8-hydroxy-2’-deoxyguanosine in rat organ, DNA and urine. Proc. Natl Acad. Scl. USA, 87, 4533-4537.
6. Gonder, J.C., Proctor, R.A. and Will, J.A. (1985) Genetic differences in oxygen toxicity are correlated with cytochrome P450 inducibility. Proc. Natl Acad. Sci. USA, 82, 6315-6319.
7. Paolini, M., Biagi, G.L., Bauer, C. and Cantelli-Forti, G. (1991) Is clonal adaptation a product of evolution over the millennia? Biochem. Pharmacol., 12, 457-158.
8. Paolmi, M., Biagi, G.L., Cantelli-Forti, G. and Bauer, C. (1994) Further mechanisms of non-genotoxic carcinogenesis. Trends Pharmacol. Sci., 15, 322-323.
9. Lubela, R., Dragnev, K.H., Chauhan, P.D., Nims, R.W., Diwan, B.A., Ward, J.M., Jones, C.R., Rice, J.M. and Miller, M.S. (1992) A pleiotropic response to phenobarbital-type enzyme inducers in the F344/NCr rat. Effects of chemicals of varied structure. Biochem. Pharmacol., 43, 1067-1078
10. Phillips, I.R., Shepard, E.A., Bayney, R.M., Pike, S.F., Rabin, B.R., Heat, R. and Carter, N. (1983) Induction and repression of the major phénobarbital induced cytochrome P450 measured by radioimmunoassay. Biochem. J„ 212, 55-64
11. Wood, A.W., Levin, W, Lu, A.Y.H., Yagi, H., Hemandez, O., Jerina, D.M. and Conney, A.H. (1976) Metabolism of benzo[a]pyrene derivatives to mutagenic products by highly purified hepatic microsomal enzymes. J. Biol. Chem., 251, 4882-1890.
12. Kasper, C.B. and Henton, D. (1980) Glucuronidation. In Jacoby, W.B. (ed.), Enzymatic Basis of Detoxification. Academic Press, New York, NY, pp. 3-12.
13. Wolf, C.R, Berry, P.N., Nash, J.A., Green, T. and Lock, E.A. (1984) Role of microsomal and cytosolic glutathione S-transferase in conjugation of hexachlor-1,3-butadiene and its possible relevance to toxicity. J. Pharmacol. Exp. Ther, 228, 202-208.
14. Runge-Morris, M. and Wilusz, J. (1994) Suppression of hydroxysteroid sulfotransferase-a gene expression by 3-methylcholanthrene. Toxicol. Appl. Pharmacol., 125, 133-141.
15. Hanna, P.E., Banks, R.B. and Marhevka, V.P. (1992) Suicide inactivation of hamster hepatic arylhydroxamic acid /V.O-acyltransferase a selective probe of.V-acelyllranstcra.se multiplicity. Mol. Pharmacol., 21, 159-168.
16. Guengerich, F.P. (1985) Enzymatic activation of chemicals to toxic metabolites. CPC Crit. Rev. Toxicol., 14, 259-307.
17. Paolini, M. and Legator, M.L. (1992) Healthy broccoli? Nature, 357, 448.
18. Gonzales, F.J. and Nebert, D.W. (1990) Evolution of the P450 gene superfamily: animal-plant ‘warfare’, molecular drive and human genetic differences in drug oxidation. Trends Genet., 6, 182-186.
19. Gonzalez, F.J., Skoda, R.C., Kimura, S., Umeno, M., Zanger, U.M., Nebert, D.W., Gelboin, H.V., Hardwick, J.P. and Meyer, U.A. (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature, 331, 442-146.
20. Daly, A.K., Cholerton, S., Gregory, W. and Idle, J.R. (1993) Metabolic polymorphisms. Pharmacol. Ther, 57, 129-160.
21. Nebert, D.W. (1991) Role of genetics and drug metabolism in human cancer risk Mutât. Res., 247, 267-281.
22. Nakachi, K., Iamai, K., Hayshi, S. and Kawayiri, K. (1993) Polymorphisms at the CYP 1A1 and glutathione S-transferase genes associated with susceptibility to cigarette dose in a Japanese population. Cancer Res., 53, 2994-2999.
23. Kalow, W. (1993) Pharmacogenetics: its biological roats and the medical challenge. Clin. Pharmacol. Ther., 54, 235-241.
24. Nebert, D.W. (1994) Drug metabolizing enzymes in ligand-modulated transcription. Biochem. Pharmacol., 47, 25-27.